Onesource Specialty Pharma Ltd (ONESOURCE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Onesource Specialty Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Transcript of Earnings call dated October 27, 2026
Transcript · 03 Nov 2026, 7:09 pm
OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its Sterile Product Division (SPD) Facility in Bengaluru.
Press Release · 30 Oct 2026, 7:37 pm
OneSource Receives USFDA EIR with VAI Status for Bengaluru Sterile Facility OneSource Specialty Pharma Limited received the Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification from the USFDA on 30th Oct'26 for its Sterile Product Division (SPD) facility in Bengaluru. This successfully closes the regulatory inspection conducted between 22nd Jun'26 and 30th Jun'26. The clearance supports the company's sterile injectable capabilities and strengthens its CDMO platform across biologics, drug-device combinations, sterile injectables, and soft gelatin capsules.
Intimation of the Audio recording of the earnings call pertaining to the unaudited financial results for the quarter and half year ended September 30, 2026
Audio / Video · 28 Oct 2026, 2:23 am
OneSource Specialty Pharma Releases Q2 Earnings Call Audio Recording OneSource Specialty Pharma Limited informed stock exchanges that the audio recording of its earnings conference call held on 27th Oct'26 at 18:30 hrs IST has been uploaded to its official website. The call discussed the company's unaudited financial results for the quarter ended 30th Sep'26 (Q2 FY27), in compliance with Regulations 30 and 46 of SEBI LODR Regulations.
OneSource announces strong Q2FY27, results revenue up 37% YoY and EBITDA up 53% YoY
Press Release · 27 Oct 2026, 4:16 pm
OneSource Reports Strong Q2FY27 Growth Driven by DDC Capacity and Commercial Launches OneSource Specialty Pharma reported Q2FY27 revenue of ₹5,162m, up 37% YoY and 15% QoQ, driven by new Drug-Device Combination (DDC) capacity, robust MSA execution, and 12 product launches. EBITDA surged 53% YoY and 32% QoQ to ₹1,633m, with margins expanding 329 bps YoY to 31.6% via operating leverage. Adjusted PAT rose 109% YoY to ₹937m, delivering an adjusted EPS of ₹8.2. Operational momentum included commercializing a second cartridge line and onboarding a US biologics partner. Management reaffirmed its FY28 outlook of $400m organic revenue with 40% steady-state EBITDA margins.
Intimation of allotment of 360 equity shares of Re.1/- each under ONESOURCE ESOP 2021 on October 27, 2026.
Others (Uncategorized) · 27 Oct 2026, 3:48 pm
OneSource Specialty Pharma Approves ESOP Share Allotment OneSource Specialty Pharma Limited approved the allotment of 360 equity shares of face value INR 1 each on 27th Oct'26 under its ESOP 2021 scheme at an exercise price of INR 278 per share (including an INR 277 premium). Following this allotment, the company's paid-up share capital increased from INR 11,46,73,791 (11,46,73,791 shares) to INR 11,46,74,151 comprising 11,46,74,151 equity shares. The newly allotted equity shares rank pari passu with the existing shares.
Intimation of change in designation of Dr. Claudio Albrecht from Independent director to Non-Executive Non-Independent Director of the Company.
Change in Management · 27 Oct 2026, 3:43 pm
OneSource Specialty Pharma Re-designates Dr. Claudio Albrecht as Non-Executive Director OneSource Specialty Pharma's Board approved the redesignation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, effective 27th Oct'26, subject to shareholder approval. Dr. Albrecht brings over three decades of global pharma experience, having previously served as CEO of Ratiopharm Group, Actavis Group, and STADA AG, as well as Co-Founder and Managing Partner of Albrecht, Prock & Partners AG. The position is liable to retirement by rotation in accordance with statutory provisions.
Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.
Outcome · 27 Oct 2026, 3:37 pm
Onesource Specialty Pharma Limited has submitted to the Exchange the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.
Outcome · 27 Oct 2026, 3:36 pm
Onesource Specialty Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 5,162 (+37.4% YoY | +15.0% QoQ) ■ EBITDA: 1,633 (+53.3% YoY | +32.4% QoQ) ■ EBITDA Margin (%): 31.6 (+329 bps YoY | +416 bps QoQ) ■ PAT: 575 (+448.2% YoY | +130.0% QoQ) ■ EPS (INR): 5.01 (+450.5% YoY | +129.8% QoQ)
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended September 30, 2026
Intimation · 27 Oct 2026, 6:30 pm
OneSource Specialty Pharma Schedules Q2FY27 Earnings Call for 27th Oct'26 OneSource Specialty Pharma Limited will host its Q2FY27 earnings conference call on Tuesday, 27th Oct'26, at 18:30 hrs IST to discuss unaudited financial results for the quarter ended 30th Sep'26. Senior management representation will include Neeraj Sharma (CEO & MD) and Anurag Bhagania (CFO). Participants can access the call via universal dial-in numbers +91 22 6280 1372 or +91 22 7115 8193, with pre-registration available via DiamondPass.
Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve OneSource Specialty ....
Intimation · 27 Oct 2026, 5:30 am
OneSource Specialty Pharma Schedules Board Meeting for Q2 FY27 Results OneSource Specialty Pharma Limited announced that its Board of Directors will meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th Sep'26. In compliance with insider trading regulations, the trading window for designated persons has been closed since 1st Oct'26 and will reopen 48 hours following the public dissemination of the financial results.
OneSource Specialty Pharma Limited has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 27 Oct 2026, 5:30 am
Allotment of 900 Equity shares of Re. 1 each under ONESOURCE ESOP 2021 on September 25, 2026
Others (Uncategorized) · 26 Sept 2026, 1:08 am
OneSource Specialty Pharma Allots 900 Equity Shares Under ESOP 2021 OneSource Specialty Pharma Limited approved the allotment of 900 equity shares of face value INR 1 each on 25th Sep'26, pursuant to the exercise of vested options under the ONESOURCE ESOP 2021 scheme. The shares were allotted at an exercise price of INR 278 per share, including a premium of INR 277 per share. Consequently, the company's paid-up equity share capital increased from INR 11,46,72,891 to INR 11,46,73,791. The newly issued equity shares rank pari passu with existing shares in all respects.
Voting results along with Scrtuinizer''s report for the 19th AGM
Annual General Meeting · 25 Sept 2026, 11:30 pm
Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026
Annual General Meeting · 11 Sept 2026, 10:32 pm
Intimation of the investor presentation
Intimation · 03 Sept 2026, 6:17 pm
OneSource Specialty Pharma Uploads Investor Presentation for Institutional Facility Visit OneSource Specialty Pharma released its latest investor presentation ahead of an institutional analyst meeting and site visit held on 3rd Sep'26. The engagement took place at the company's Unit II manufacturing facility in Bengaluru. The updated presentation is now accessible on the company's investor relations website, providing stakeholders with current operational insights tied to the facility tour.
Intimation of the Notice of the 19th AGM (2nd AGM after listing), to be held on September 23, 2026 at 5:00 pm through Video Conferencing or other Audio Visual Means
Annual General Meeting · 01 Sept 2026, 2:08 am
Business Responsibility and Sustainability Report for the FY 2026
Others (Uncategorized) · 01 Sept 2026, 2:04 am
OneSource Specialty Pharma FY26 Sustainability & Business Responsibility Report Highlights OneSource submitted its BRSR for FY26, ended on 31-Mar'26, detailing key operational and ESG metrics. Exports contributed 70.80% to standalone turnover. The company had 1,200 permanent employees and 1,089 workers with nil differently-abled individuals. The permanent employee turnover rate was 23%. FY26 spending on employee well-being was 1.12% of total revenue. Sales to related parties stood at 29.12%, down from 54.14% in FY25. Investments in related parties constituted 99.54% of total investments. The company reported zero work-related injuries or fatalities.
Annual Report for FY 2025-26
Others (Uncategorized) · 01 Sept 2026, 2:02 am
Annual Report for FY 2025-26
Others (Uncategorized) · 01 Sept 2026, 2:00 am
Intimation of Investors called scheduled on September 03, 2026 at 10:00 AM.
Intimation · 01 Sept 2026, 12:34 am
OneSource Specialty Pharma Schedules Group Investor Meeting OneSource Specialty Pharma Limited will hold a physical group investor meeting on Sep 03, 2026. The meeting will take place at its Unit 2 manufacturing facility in Bengaluru. Company representatives will discuss publicly available information, including business overview, strategy, industry trends, and growth outlook. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared during the interaction.
Intimation of Credit Rating issued by India Ratings and Research Private Limited vide press release dated August 17, 2026
Others (Uncategorized) · 18 Aug 2026, 5:53 pm
OneSource Specialty Pharma's Credit Rating Upgraded by India Ratings India Ratings & Research upgraded OneSource Specialty Pharma's long-term bank facility rating to 'IND A'/Positive from 'IND A-'. The short-term rating was affirmed at 'IND A1'. The upgrade, dated 17 Aug '26, reflects a strengthening business profile from the commercialization of its drug-device platform and GLP-1 supplies, improving revenue visibility. 1QFY27 revenue grew 37.2% YoY to INR 4.5bn with EBITDA up 39.4% to INR 1.2bn. However, FY26 net leverage increased to 4.7x from 1.6x due to capex, with significant contingent liabilities noted.
Intimation of Transcript of Earnings call dated July 25, 2026
Transcript · 31 Jul 2026, 6:14 pm
Changes in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Change in Management · 28 Jul 2026, 12:26 am
OneSource Announces Senior Management Changes OneSource Specialty Pharma announced senior management changes effective 24 Jul'26. Preeti Kalra, Head of Human Resources, has been designated as Senior Management Personnel (SMP). She brings over 25 years of HR leadership experience from firms including Stelis Biopharma and Biocon Biologics. Concurrently, Ravi Kumar, Global Head of Injectables and Head of Corporate Strategy, resigned from his SMP position effective the same day, citing personal reasons. These changes represent a key leadership shuffle at the specialty pharma company.
Intimation of Audio Recording of Earnings call pertaining to the Unaudited Financial Results for the quarter ended June 30, 2026
Intimation · 25 Jul 2026, 7:52 pm
OneSource Pharma Makes Q1 FY27 Earnings Call Recording Available OneSource Specialty Pharma has published the audio recording of its earnings call held on Jul 25, 2026. The call discussed the company's unaudited financial results for the quarter ended Jun 30, 2026 (Q1 FY27). The recording is accessible on the company's official website, as per SEBI regulations. This provides investors and analysts direct access to management's commentary and performance discussion for the first quarter of the fiscal year.